TLSI TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. (TLSI) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $61.4K.
Where they traded
Last open-market purchase: May 15, 2026 , by Szela Mary T .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Stansky Michael P 2 fills | Director | Buy | 610,000 | $2.50 | $1.5M | 1,240,722 | |
| Wahlstrom Mats | Director | Buy | 60,000 | $2.53 | $151.8K | 147,555 | |
| Szela Mary T | CEO and President | Buy | 39,682 | $2.59 | $102.8K | 1,065,215 | |
| Gordon Gary B. | Director | Buy | 10,000 | $2.46 | $24.6K | 72,510 | |
| Patience David | Chief Financial Officer | Buy | 7,100 | $2.43 | $17.3K | 275,757 | |
| Marshak Richard | Chief Commercial Officer | Sell | 543 | $2.67 | $1.4K | 125,101 −0.4% of holding | |
| Szela Mary T | CEO and President | Sell | 15,944 | $3.85 | $61.4K | 752,987 −2.1% of holding | |
| Stevens Jennifer | Chief Regulatory Officer | Sell | 774 | $4.12 | $3.2K | 124,110 −0.6% of holding | |
| Cox Bryan F. | Chief of Research | Sell | 579 | $4.12 | $2.4K | 163,415 −0.4% of holding | |
| Marshak Richard | Chief Commercial Officer | Sell | 419 | $4.12 | $1.7K | 110,397 −0.4% of holding | |
| Devlin Jodi | Chief of Clinical Operations | Sell | 273 | $4.12 | $1.1K | 97,364 −0.3% of holding | |
| Devlin Jodi | Chief of Clinical Operations | Sell | 1,772 | $4.09 | $7.2K | 97,637 −1.8% of holding | |
| Marshak Richard | Chief Commercial Officer | Sell | 1,589 | $4.09 | $6.5K | 110,816 −1.4% of holding | |
| Stevens Jennifer | Chief Regulatory Officer | Sell | 1,552 | $4.09 | $6.3K | 124,884 −1.2% of holding | |
| Cox Bryan F. | Chief of Research | Sell | 1,467 | $4.09 | $6.0K | 163,994 −0.9% of holding | |
| Szela Mary T | CEO and President | Sell | 4,358 | $4.13 | $18.0K | 768,931 −0.6% of holding | |
| Marshak Richard | Chief Commercial Officer | Sell | 1,449 | $4.13 | $6.0K | 112,405 −1.3% of holding | |
| Stevens Jennifer | Chief Regulatory Officer | Sell | 1,204 | $4.13 | $5.0K | 126,436 −0.9% of holding | |
| Devlin Jodi | Chief of Clinical Operations | Sell | 1,162 | $4.13 | $4.8K | 99,409 −1.2% of holding | |
| Cox Bryan F. | Chief of Research | Sell | 1,138 | $4.13 | $4.7K | 165,461 −0.7% of holding | |
| Stansky Michael P 2 fills | Director | Buy | 361,098 | $4.10 | $1.5M | 787,132 | |
| Szela Mary T | CEO and President | Buy | 30,487 | $4.10 | $125.0K | 773,289 | |
| Valle William | Director | Buy | 30,487 | $4.10 | $125.0K | 30,487 | |
| Gordon Gary B. | Director | Buy | 9,756 | $4.10 | $40.0K | 9,756 | |
| Patience David | Chief Financial Officer | Buy | 3,657 | $4.10 | $15.0K | 268,657 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.